Join
Live feed
·
PRReleasevia Quantisnow
Disc Medicine Inc. logo

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

ByQuantisnow·Wall Street's wire, on your screen.
IRON· Disc Medicine Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IRON (Disc Medicine Inc.) and more on Quantisnow.